P. Twardowski

507 total citations
26 papers, 405 citations indexed

About

P. Twardowski is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, P. Twardowski has authored 26 papers receiving a total of 405 indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Pulmonary and Respiratory Medicine, 14 papers in Oncology and 7 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in P. Twardowski's work include Prostate Cancer Treatment and Research (15 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Bone health and treatments (4 papers). P. Twardowski is often cited by papers focused on Prostate Cancer Treatment and Research (15 papers), Radiopharmaceutical Chemistry and Applications (7 papers) and Bone health and treatments (4 papers). P. Twardowski collaborates with scholars based in United States, Canada and United Kingdom. P. Twardowski's co-authors include H. William Schnaper, Stephen Gately, Lisa Boggio, M. Sharon Stack, Noël Bouck, Jan J. Enghild, Hau C. Kwaan, Gerald A. Soff, Marjorie L. Patrick and Laird D. Madison and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

P. Twardowski

25 papers receiving 398 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
P. Twardowski United States 8 227 182 169 109 58 26 405
Hideki Terai Japan 15 480 2.1× 199 1.1× 358 2.1× 297 2.7× 33 0.6× 41 778
A. Marije Hoogland Netherlands 13 408 1.8× 278 1.5× 347 2.1× 112 1.0× 32 0.6× 16 695
Jincai Wu China 12 309 1.4× 185 1.0× 126 0.7× 138 1.3× 14 0.2× 29 566
Peter Hamer United States 12 189 0.8× 208 1.1× 54 0.3× 226 2.1× 45 0.8× 22 457
Sara Zaghlul United States 5 300 1.3× 144 0.8× 127 0.8× 260 2.4× 100 1.7× 8 492
Edward W. Arfman United States 10 176 0.8× 99 0.5× 241 1.4× 165 1.5× 65 1.1× 13 442
M. Ferrero-Poüs France 8 112 0.5× 231 1.3× 65 0.4× 228 2.1× 76 1.3× 10 432
George M. Yousef Canada 11 427 1.9× 337 1.9× 127 0.8× 54 0.5× 16 0.3× 20 576
Antje Krohn Germany 11 371 1.6× 213 1.2× 437 2.6× 129 1.2× 32 0.6× 17 643
D. Grabau Denmark 9 217 1.0× 167 0.9× 60 0.4× 140 1.3× 45 0.8× 11 371

Countries citing papers authored by P. Twardowski

Since Specialization
Citations

This map shows the geographic impact of P. Twardowski's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P. Twardowski with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P. Twardowski more than expected).

Fields of papers citing papers by P. Twardowski

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P. Twardowski. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P. Twardowski. The network helps show where P. Twardowski may publish in the future.

Co-authorship network of co-authors of P. Twardowski

This figure shows the co-authorship network connecting the top 25 collaborators of P. Twardowski. A scholar is included among the top collaborators of P. Twardowski based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P. Twardowski. P. Twardowski is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gańczak, Maria, et al.. (2024). “Why would we?” A qualitative study on COVID-19 vaccination decision making among Ukrainian economic female migrants in Poland. Frontiers in Public Health. 12. 1380627–1380627. 3 indexed citations
2.
Lange, Leslie A., Peter Lee, Marcin Kortylewski, et al.. (2024). Initial Results of a Phase 2 Trial of Stereotactic Body Radiation Therapy, Hormone/Androgen Deprivation Therapy and Radium 223 Dichloride for Oligometastatic Castrate Sensitive Prostate Cancer (SHARP). International Journal of Radiation Oncology*Biology*Physics. 120(2). S147–S148. 1 indexed citations
3.
4.
Dandapani, Savita, Tanya B. Dorff, Marcin Kortylewski, Paul Frankel, & P. Twardowski. (2019). Radium 223 Dichloride in Combination with Androgen Deprivation Therapy and Stereotactic Body Radiation Therapy for Patients with Stage IV Oligometastatic Castration Sensitive Prostate Cancer: Clinical Trial in Progress. International Journal of Radiation Oncology*Biology*Physics. 104(5). 1193–1193. 3 indexed citations
5.
Twardowski, P., Melissa L. Johnson, Mark N. Stein, et al.. (2019). A phase I trial of GEN-009, a neoantigen vaccine using ATLAS™, an autologous immune assay, to identify immunogenic and inhibitory tumour mutations. Annals of Oncology. 30. v479–v479. 2 indexed citations
6.
Lara, Primo N., Melissa Plets, Catherine M. Tangen, et al.. (2018). Bone turnover biomarkers identify unique prognostic risk groups in men with castration resistant prostate cancer and skeletal metastases: Results from SWOG S0421. Cancer Treatment and Research Communications. 16. 18–23. 4 indexed citations
7.
Bellmunt, Joaquim, Bernhard J. Eigl, Elżbieta Senkus, et al.. (2017). Borealis-1: a randomized, first-line, placebo-controlled, phase II study evaluating apatorsen and chemotherapy for patients with advanced urothelial cancer. Annals of Oncology. 28(10). 2481–2488. 19 indexed citations
8.
9.
Sampath, Sagus, Bertram Yuh, Paul Frankel, et al.. (2016). Prostate Bed Stereotactic Body Radiation Therapy (PB-SBRT) for Postprostatectomy Biochemical Recurrence: First Toxicity Results of a Phase 1 Dose-Escalation Trial. International Journal of Radiation Oncology*Biology*Physics. 96(2). E227–E228. 3 indexed citations
10.
Cheng, Heather H., Roman Gulati, Arun Azad, et al.. (2015). Activity of enzalutamide in men with metastatic castration-resistant prostate cancer is affected by prior treatment with abiraterone and/or docetaxel. Prostate Cancer and Prostatic Diseases. 18(2). 122–127. 71 indexed citations
11.
Vanderwalde, Ari M., Paul Frankel, L. Leong, et al.. (2012). Long-Term Survival after High-Dose Chemotherapy Followed by Peripheral Stem Cell Rescue for High-Risk, Locally Advanced/Inflammatory, and Metastatic Breast Cancer. Biology of Blood and Marrow Transplantation. 18(8). 1273–1280. 6 indexed citations
12.
Portnow, Jana, Paul Frankel, P. Twardowski, et al.. (2011). A phase I study of bortezomib and temozolomide in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology. 69(2). 505–514. 10 indexed citations
13.
Goldkorn, Amir, Tao Xu, Binfeng Lu, et al.. (2010). Circulating tumor cell capture and analysis in a multicenter SWOG-coordinated prostate cancer trial.. Journal of Clinical Oncology. 28(15_suppl). TPS342–TPS342. 1 indexed citations
14.
Twardowski, P., Walter M. Stadler, Paul Frankel, et al.. (2009). Phase II study of aflibercept (VEGF-Trap) in patients (pts) with recurrent or metastatic transitional cell carcinoma (TCC) of the urothelium: A California Cancer Consortium trial. Journal of Clinical Oncology. 27(15_suppl). e16030–e16030. 8 indexed citations
15.
16.
Chung, Vincent, Christopher Ruel, Thehang Luu, et al.. (2008). Randomized pilot trial of oral cyclophosphamide versus oral cyclophosphamide with celecoxib for recurrent or persistent epithelial ovarian, fallopian tube or primary peritoneal cancer: preliminary data. Journal of Clinical Oncology. 26(15_suppl). 16555–16555. 3 indexed citations
17.
Twardowski, P., Warren Chow, Marianna Koczywas, et al.. (2005). Phase I trial of oral cyclophosphamide in combination with celecoxib in patients with advanced malignancies. Journal of Clinical Oncology. 23(16_suppl). 3196–3196.
18.
Lara, Primo N., Jeff Longmate, Walter M. Stadler, et al.. (2005). Markers of bone metabolism predict survival in hormone refractory prostate cancer (HRPC): Results from a randomized California Cancer Consortium & University of Chicago trial. Journal of Clinical Oncology. 23(16_suppl). 4569–4569. 4 indexed citations
19.
Lara, Primo N., Jeff Longmate, Walter M. Stadler, et al.. (2004). Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. Journal of Clinical Oncology. 22(14_suppl). 4647–4647. 1 indexed citations
20.
Lara, Primo N., Jeff Longmate, David I. Quinn, et al.. (2004). Angiogenesis inhibition in metastatic hormone refractory prostate cancer (HRPC): A randomized phase II trial of two doses of the matrix metalloproteinase inhibitor (MMPI) BMS-275291. Journal of Clinical Oncology. 22(14_suppl). 4647–4647. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Hideki Terai Breakdown of academic impact, for papers by A. Marije Hoogland Breakdown of academic impact, for papers by Jincai Wu Breakdown of academic impact, for papers by Peter Hamer Breakdown of academic impact, for papers by Sara Zaghlul Breakdown of academic impact, for papers by Edward W. Arfman Breakdown of academic impact, for papers by M. Ferrero-Poüs Breakdown of academic impact, for papers by George M. Yousef Breakdown of academic impact, for papers by Antje Krohn Breakdown of academic impact, for papers by D. Grabau
Rankless by CCL
2026